Astra has appointed an outsider in Pascal Soriot, who takes over from interim CEO Simon Lowth in October. Lowth will return to being finance director.
In contrast, Barclays has chosen an insider, Antony Jennings, the former boss of retail and commercial banking, to take over as CEO. But it also has a new chairman in the form of Sir David Walker, who assumes the role in November. And with Antony Jennings stepping up from what has been the Cinderella side of Barclays' business, in reality there are two new brooms at Barclays.
Both management teams face considerable challenges. Astra is facing its well-known patent cliff. About half of its current revenue stream will expire by 2016, when several drugs lose their patent protection.
There are three, or possibly four courses of action it can take. It can strive to develop new patented drugs through R&D, a strategy that it has pursued with singular and unfortunate lack of success so far. It can buy new drug formulae through M&A. It can diversify into generic drugs or consumer health, like rival GlaxoSmithKline. Or it could possibly run itself as a cash cow and eventually find a buyer.
Pascal Soriot's appointment suggests the company will persevere with the R&D route. He was formerly chief operating officer of Roche, the R&D-led drugs and diagnostics company. Before that, he was CEO of U.S. biologicals business Genentech, which he merged into Roche, having trained as a vet before moving into the pharmaceuticals industry.
Announcing the appointment, chairman Leif Johansson told the Financial Times that he expected no dramatic change from the current strategy, though with a greater open-mindedness to partnerships with other organizations.
That's in contrast to the strategy we might have seen from Simon Lowth if he had been confirmed in post. In his short tenure, he secured a deal with Bristol-Myers Squibb to jointly acquire biotech company Amylin. It seemed to point to an innovative M&A strategy that might have presaged a quick change in Astra's fortunes.
Instead, investors will need to be patient while they see if Soriot can get more out of Astra's R&D department than his predecessor.
Patience is a virtue that Barclays' investors will also be in need of. The new team's agenda is to cut Barclays' investment banking division down to size and restore the bank's tattered reputation. David Walker has been vocal over his desire to cut remuneration in the investment bank, which is tantamount to the same thing.
That's all well and good. In the long run, it should make Barclays a better, safer, more utility-like bank. Jennings has said that it will take three to five years to turn it around and has promised to present a transformation plan by the first quarter of next year.
But it's all about cutting income, not about growth. Investment banking contributes over 60% of Barclays' pre-tax profit. There is no short-term fix to replace that income stream. Indeed, Jennings has scrapped his predecessor's 15% RoE target in favor of something just north of Barclays' 11.5% cost of capital. It may seem academic when last year's actual RoE was just 7%, but a target to not actually destroy capital is modest.
In the meantime, there is considerable execution risk. Jennings has virtually no investment banking experience. David Walker has held senior positions at Morgan Stanley but can hardly claim to have gotten his hands dirty in the trading pit. The investment bank is run by Rich Ricci, a former close lieutenant of Bob Diamond. It remains to be seen how safely the top two can cut the investment bank down to size.
One of these companies is a long-term hold of high-income investment star Neil Woodford, while the other he has avoided with the proverbial barge pole. It may not be hard to guess which is which, but to find out for certain, and learn more of his methods, you can download this free report from the Motley Fool: "8 Shares Held by Britain's Super Investor."
More investment opportunities:
- Another Reason to Sell RBS
- How to Unearth Great Oil and Gas Shares
- 10 Steps To Making A Million In The Market
Tony owns shares in AstraZeneca and GlaxoSmithKline but no other shares mentioned in this article.